Canaccord Genuity Rates Zevra Therapeutics (ZVRA) buy

Canaccord Genuity's analyst reiterates a buy rating for Zevra Therapeutics, setting a price target of $29, a 123.77% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:12 PM EDT · Updated Jun 13, 2026, 1:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Canaccord Genuity rated Zevra Therapeutics, Inc. ($ZVRA) "buy" with a $29 price target on June 11, 2026.

Since the rating, $ZVRA is down 0.5% after 1 week, up 1.6% after 1 month and down 23.4% to date (from the $12.97 close on Jun 11, 2026).

ZVRA Zevra Therapeutics, Inc.

$9.94 +19.18% year to date

Daily close · Oct 16, 2026

Key Points

Canaccord Genuity reiterated its buy rating on Zevra Therapeutics, Inc. (ZVRA) with a price target of $29 on June 11, 2026.
The stock is currently trading at $12.96, which is well below the estimated target, suggesting significant upside potential.
Zevra Therapeutics has a market capitalization of approximately $693 million and a forward P/E ratio of 10.84.

Get $ZVRA trade alerts by text

We text you when insiders, Congress or big funds trade $ZVRA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Zevra Therapeutics, Inc. alert may contain errors. Disclosures

Analysts Set New Price Targets

On June 11, 2026, Canaccord Genuity's analyst Sumant Kulkarni reiterated a buy rating for Zevra Therapeutics, Inc. (ZVRA) with a price target of $29. This update reflects confidence in the company's growth potential, especially as the stock trades at $12.96, considerably lower than the target price.

Stock Price Context

ZVRA is currently priced at $12.96, which is below its 52-week high of $15.04 and well above its low of $7.88. This positioning suggests that the stock may have room to grow, especially in light of the new price target from Canaccord Genuity. The forward P/E ratio of 10.84 indicates the stock is trading at a reasonable valuation for a company within the biotechnology sector.

12-month forecast

$ZVRA price target

Zevra Therapeutics, Inc. daily closes and this analyst's $29 target. Not advice.

Other Analyst Opinions

Several other firms have also weighed in on ZVRA recently. HC Wainwright & Co. reiterated its buy rating with a price target of $26 on August 20, 2026. Guggenheim maintained a buy rating but lowered its target to $23 on August 7, 2026. Citizens Bank also kept a market outperform rating with a revised target of $28 on August 6, 2026. These ratings point to a generally positive outlook among analysts, with most maintaining a bullish stance despite slight adjustments in target prices.

What ZVRA Does

Zevra Therapeutics, Inc. focuses on developing treatments for rare diseases. Its lead product candidate, KP1077, is undergoing Phase 3 clinical trials for idiopathic hypersomnia and narcolepsy. The company also markets treatments for conditions like ADHD and urea cycle disorders. The latest analyst ratings signal optimism about its future performance and potential market impact.

What's Ahead for ZVRA

Investors will be watching closely as Zevra Therapeutics is scheduled to report its next earnings on November 4, 2026. The ongoing developments in their clinical trials and how they align with analyst expectations will be crucial in the coming months. Remember, the latest rating and target from Canaccord Genuity reflects data as of June 11, and future filings may show changes in these positions.